Effectiveness of BioTissue’s Products to be Presented at ASCRS

MIAMI, Fla., May 5, 2016 – BioTissue^®, Inc., the industry leader in regenerative tissue therapies and ocular hygiene products for lid margin and ocular surface diseases, announced today that papers and posters demonstrating the clinical effectiveness of its products will be presented at this week’s ASCRS 2016, taking place May 6-10 in New Orleans.

The papers, posters and videos being presented will demonstrate cryopreserved amniotic membrane’s beneficial effects of promoting corneal wound healing. More specifically, Prokera^® will be shown to promote corneal nerve regeneration in dry eye and promote healing in post-operative indications such as DMEK and high risk PKP. Additionally, the Shunt Tube Exposure Prevention Study presentation will demonstrate the superiority of UC-Guard compared to other patch grafts, and an FDA Phase 1 Demodex Blepharitis treatment study poster will show the safety of using 4-Terpineol, found in Cliradex^®, in treating Demodex Blepharitis.

“We are pleased that these posters and papers demonstrating the clinical effectiveness of our cryopreserved amniotic tissue based products are being showcased at this year’s ASCRS,” said Thomas G. Daniells, Chief Commercial Officer, BioTissue. “The evidence provided in these posters and papers demonstrate improved clinical outcomes and that our products are helping ophthalmologists treat a number of diseases and conditions. Our innovative products are helping to improve the quality of life of their patients.”

Details of each presentation include:

Prokera^®

• Corneal Nerve Regeneration after Self-Retained Amniotic Membrane Use for Dry-Eye Disease, Thomas John, MD, 3-A Cornea: Dry Eye.
• Enhancing Wound Healing After Descemet Membrane Endothelial Keratoplasty, Thomas John, MD, on demand kiosks in poster pavilion.

AmnioGraft^®

• Penetrating Keratoplasty in Pre-phthisis Eye, Hosam El Sheha, MD, on demand kiosks in film pavilion.
• Sealing the Gap in Recurrent Pterygium, Anny Cheng, MD, on demand kiosks in film pavilion.

UC-Guard

• Amniotic Membrane–Umbilical Cord Versus Pericardium Patch Grafts to Prevent Tube Exposure: Randomized Clinical Trial, Richard Lee, MD, 3-H Glaucoma: Surgical Technique.

Cliradex^®

• Demodex Blepharitis Treatment Study, Hosam El Sheha, MD, on demand kiosks in poster pavilion.

BioTissue is featuring its cryopreserved amniotic membrane ocular wound healing products, including Prokera, and its all natural, preservative-free lid, lash and facial cleanser, Cliradex, at its Booth #1717. BioTissue will also hold a Speaker’s Forum at its booth #1717 with distinguished guest speakers throughout the conference.

About BioTissue
BioTissue, Inc. is a subsidiary of TissueTech^™, a privately held biotechnology company that develops innovative wound healing and hygiene solutions for the prevention and treatment of ocular surface diseases and disorders. BioTissue provides a comprehensive line of cryopreserved amniotic membrane ocular wound healing products, including AmnioGraft^®, a biologic ocular transplantation graft; AmnioGuard^®, a biologic glaucoma shunt tube graft; and the Prokera family of biologic corneal bandage devices. These products incorporate human amniotic membrane processed with the Company’s proprietary CryoTek^® method proven to preserve the biological properties of amniotic membrane and umbilical cord tissue essential for anti-inflammatory and anti-scarring effects compared with the dehydration method that drastically alters the structural and biological integrity of this tissue.1 BioTissue also developed and markets the Cliradex^®line of products, a natural lid, lash and facial cleanser with 4-Terpineol, the active component of tea tree oil (TTO), for the management of symptoms in ocular diseases such as blepharitis, Demodex, and rosacea. For more information, visit www.biotissue.com.